Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Valeant

- PMLiVE

GSK/ Valeant’s Trobalt set for EU restrictions

Eye concerns prompt CHMP to recommend last-line use for the epilepsy drug

- PMLiVE

Valeant buys Bausch + Lomb for $8.7bn

Biggest deal yet for acquisition-hungry Canadian pharma company

- PMLiVE

Death leads to recall of batch of Takeda’s Rienso in Switzerland

Marketing partner Amag also reports three other hypersensitivity reactions

- PMLiVE

New vortioxetine studies reinforce efficacy in depression

Supports marketing applications from Takeda and Lundbeck

- PMLiVE

Takeda rides out Actos decline as fiscal 2012 sales rise

Nycomed acquisition continues to bolster revenues

- PMLiVE

Takeda buys vaccines specialist Inviragen

Acquires vaccine candidates against dengue fever and hand, foot and mouth disease in $250m deal

- PMLiVE

Shire misses Q1 targets as Replagal sales fall

Reduces 2013 revenue forecasts

- PMLiVE

Sanofi launches diabetes drug Lyxumia in the UK

Says drug could make multimillion pound savings for the NHS

- PMLiVE

Rumoured Valeant merger with Actavis stalls

Wall Street Journal claims talks have fallen through on $13bn merger

- PMLiVE

Union calls on AstraZeneca to reconsider Alderley Park plans

Unite says move to Cambridge will take years to deliver value

ABPI London offices

ABPI: Pharma must sell outcomes, not products

Annual conference told industry must re-establish its social contract with the NHS

- PMLiVE

US-based Millennium launches blood cancer website

The Takeda Oncology Company roll out new multiple myeloma website

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links